These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

512 related items for PubMed ID: 29966420

  • 1. Development of a Janus Kinase Inhibitor Prodrug for the Treatment of Rheumatoid Arthritis.
    Wei X, Wu J, Zhao G, Galdamez J, Lele SM, Wang X, Liu Y, Soni DM, Purdue PE, Mikuls TR, Goldring SR, Wang D.
    Mol Pharm; 2018 Aug 06; 15(8):3456-3467. PubMed ID: 29966420
    [Abstract] [Full Text] [Related]

  • 2. A Macromolecular Janus Kinase (JAK) Inhibitor Prodrug Effectively Ameliorates Dextran Sulfate Sodium-Induced Ulcerative Colitis in Mice.
    Zhao G, Wei X, Wu J, Eichele DD, Lele SM, Yang L, Zhang F, Wang D.
    Pharm Res; 2019 Mar 11; 36(4):64. PubMed ID: 30859327
    [Abstract] [Full Text] [Related]

  • 3. JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production.
    LaBranche TP, Jesson MI, Radi ZA, Storer CE, Guzova JA, Bonar SL, Thompson JM, Happa FA, Stewart ZS, Zhan Y, Bollinger CS, Bansal PN, Wellen JW, Wilkie DP, Bailey SA, Symanowicz PT, Hegen M, Head RD, Kishore N, Mbalaviele G, Meyer DM.
    Arthritis Rheum; 2012 Nov 11; 64(11):3531-42. PubMed ID: 22899318
    [Abstract] [Full Text] [Related]

  • 4. Development of a macromolecular prodrug for the treatment of inflammatory arthritis: mechanisms involved in arthrotropism and sustained therapeutic efficacy.
    Quan LD, Purdue PE, Liu XM, Boska MD, Lele SM, Thiele GM, Mikuls TR, Dou H, Goldring SR, Wang D.
    Arthritis Res Ther; 2010 Nov 11; 12(5):R170. PubMed ID: 20836843
    [Abstract] [Full Text] [Related]

  • 5. Quantitative tracking of inflammatory activity at the peak and trough plasma levels of tofacitinib, a Janus kinase inhibitor, via in vivo 18 F-FDG PET.
    Raychaudhuri S, Abria C, Harmany ZT, Smith CM, Kundu-Raychaudhuri S, Raychaudhuri SP, Chaudhari AJ.
    Int J Rheum Dis; 2019 Dec 11; 22(12):2165-2169. PubMed ID: 31659868
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis.
    Hodge JA, Kawabata TT, Krishnaswami S, Clark JD, Telliez JB, Dowty ME, Menon S, Lamba M, Zwillich S.
    Clin Exp Rheumatol; 2016 Dec 11; 34(2):318-28. PubMed ID: 26966791
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Role of janus kinase inhibitors in the treatment of alopecia areata.
    Triyangkulsri K, Suchonwanit P.
    Drug Des Devel Ther; 2018 Dec 11; 12():2323-2335. PubMed ID: 30100707
    [Abstract] [Full Text] [Related]

  • 12. Janus kinase inhibitors: An innovative treatment for alopecia areata.
    Park H, Yu DA, Kwon O.
    J Dermatol; 2019 Aug 11; 46(8):724-730. PubMed ID: 31237712
    [Abstract] [Full Text] [Related]

  • 13. Tofacitinib Suppresses Several JAK-STAT Pathways in Rheumatoid Arthritis In Vivo and Baseline Signaling Profile Associates With Treatment Response.
    Palmroth M, Kuuliala K, Peltomaa R, Virtanen A, Kuuliala A, Kurttila A, Kinnunen A, Leirisalo-Repo M, Silvennoinen O, Isomäki P.
    Front Immunol; 2021 Aug 11; 12():738481. PubMed ID: 34630419
    [Abstract] [Full Text] [Related]

  • 14. The Janus kinase inhibitor tofacitinib inhibits TNF-α-induced gliostatin expression in rheumatoid fibroblast-like synoviocytes.
    Kawaguchi Y, Waguri-Nagaya Y, Tatematsu N, Oguri Y, Kobayashi M, Nozaki M, Asai K, Aoyama M, Otsuka T.
    Clin Exp Rheumatol; 2018 Aug 11; 36(4):559-567. PubMed ID: 29352846
    [Abstract] [Full Text] [Related]

  • 15. Preclinical to clinical translation of tofacitinib, a Janus kinase inhibitor, in rheumatoid arthritis.
    Dowty ME, Jesson MI, Ghosh S, Lee J, Meyer DM, Krishnaswami S, Kishore N.
    J Pharmacol Exp Ther; 2014 Jan 11; 348(1):165-73. PubMed ID: 24218541
    [Abstract] [Full Text] [Related]

  • 16. Regulation of inflammatory responses in tumor necrosis factor-activated and rheumatoid arthritis synovial macrophages by JAK inhibitors.
    Yarilina A, Xu K, Chan C, Ivashkiv LB.
    Arthritis Rheum; 2012 Dec 11; 64(12):3856-66. PubMed ID: 22941906
    [Abstract] [Full Text] [Related]

  • 17. Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland.
    Finckh A, Tellenbach C, Herzog L, Scherer A, Moeller B, Ciurea A, von Muehlenen I, Gabay C, Kyburz D, Brulhart L, Müller R, Hasler P, Zufferey P, physicians and patients of the SCQM.
    RMD Open; 2020 May 11; 6(1):. PubMed ID: 32385143
    [Abstract] [Full Text] [Related]

  • 18. Osteoimmunology in rheumatoid and psoriatic arthritis: potential effects of tofacitinib on bone involvement.
    Orsolini G, Bertoldi I, Rossini M.
    Clin Rheumatol; 2020 Mar 11; 39(3):727-736. PubMed ID: 31970549
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition.
    Dowty ME, Lin TH, Jesson MI, Hegen M, Martin DA, Katkade V, Menon S, Telliez JB.
    Pharmacol Res Perspect; 2019 Dec 11; 7(6):e00537. PubMed ID: 31832202
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.